Safety and Efficacy of Extended Therapy with [<sup>177</sup>Lu]Lu-PSMA: A German Multicenter Study-Reference-Cited by-同舟云学术

Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA: A German Multicenter Study

Published:2024-05-02 Issue:6 Volume:65 Page:909-916
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Seifert Robert,Telli Tugce,Lapa Constantin,Desaulniers Mélanie,Hekimsoy Turkay,Weber Wolfgang A.,Pfob Christian,Hadaschik Boris,Bögemann Martin,Schäfers Michael,Herrmann Ken,Rahbar Kambiz,Eiber Matthias,Fendler Wolfgang P.

Publisher

Society of Nuclear Medicine

Reference17 articles.

1. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

3. Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer;Yordanova;Eur J Nucl Med Mol Imaging.,2019

4. Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer

5. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-03

2. PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-03

3. Future Perspectives of Artificial Intelligence in Bone Marrow Dosimetry and Individualized Radioligand Therapy;Seminars in Nuclear Medicine;2024-07